BRPI0507530A - preparação para liberação prolongada, agente para evitar ou tratar doença, processo para produzir a preparação para liberação prolongada, método para evitar ou tratar doença, e, uso da preparação para liberação prolongada - Google Patents

preparação para liberação prolongada, agente para evitar ou tratar doença, processo para produzir a preparação para liberação prolongada, método para evitar ou tratar doença, e, uso da preparação para liberação prolongada

Info

Publication number
BRPI0507530A
BRPI0507530A BRPI0507530-0A BRPI0507530A BRPI0507530A BR PI0507530 A BRPI0507530 A BR PI0507530A BR PI0507530 A BRPI0507530 A BR PI0507530A BR PI0507530 A BRPI0507530 A BR PI0507530A
Authority
BR
Brazil
Prior art keywords
extended release
release preparation
treating disease
preventing
agent
Prior art date
Application number
BRPI0507530-0A
Other languages
English (en)
Inventor
Kazuhiro Saito
Tomomichi Futo
Tetsuo Hoshino
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0507530A publication Critical patent/BRPI0507530A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PREPARAçãO PARA LIBERAçãO PROLONGADA, AGENTE PARA EVITAR OU TRATAR DOENçA, PROCESSO PARA PRODUZIR A PREPARAçãO PARA LIBERAçãO PROLONGADA, MéTODO PARA EVITAR OU TRATAR DOENçA, E, USO DA PREPARAçãO PARA LIBERAçãO PROLONGADA" Preparação para liberação prolongada que compreende a combinação de um micro-cápsula capaz de liberar, de forma prolongada, um agonista GnRH, ou um sal do mesmo, durante um prazo longo, com outra micro-cápsula capaz de liberar, de forma prolongada, o agonista GnRH, ou um sal do mesmo, durante um prazo curto.
BRPI0507530-0A 2004-02-10 2005-02-09 preparação para liberação prolongada, agente para evitar ou tratar doença, processo para produzir a preparação para liberação prolongada, método para evitar ou tratar doença, e, uso da preparação para liberação prolongada BRPI0507530A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004034180 2004-02-10
PCT/JP2005/001922 WO2005074896A1 (ja) 2004-02-10 2005-02-09 徐放性製剤

Publications (1)

Publication Number Publication Date
BRPI0507530A true BRPI0507530A (pt) 2007-07-03

Family

ID=34836170

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507530-0A BRPI0507530A (pt) 2004-02-10 2005-02-09 preparação para liberação prolongada, agente para evitar ou tratar doença, processo para produzir a preparação para liberação prolongada, método para evitar ou tratar doença, e, uso da preparação para liberação prolongada

Country Status (9)

Country Link
US (1) US7662408B2 (pt)
EP (1) EP1714643A4 (pt)
JP (1) JP4966545B2 (pt)
KR (1) KR101162526B1 (pt)
CN (1) CN1938008A (pt)
BR (1) BRPI0507530A (pt)
CA (1) CA2554262A1 (pt)
TW (1) TW200529890A (pt)
WO (1) WO2005074896A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
EP2296624A1 (de) * 2008-06-09 2011-03-23 Boehringer Ingelheim International GmbH Neue emulsionen zur herstellung von arzneimitteln
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
KR101113044B1 (ko) * 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
WO2011161531A1 (en) * 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
EP2585091B1 (en) * 2010-06-25 2014-09-10 Takeda Pharmaceutical Company Limited Sustained-release formulation comprising a metastin derivative
WO2012134441A1 (en) * 2011-03-29 2012-10-04 Empire Technology Development Llc Microcapsule corrosion control in reinforced concrete
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN102552215B (zh) * 2012-02-02 2014-08-13 浙江海正药业股份有限公司 微囊冻干粉及其制备方法
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
AU2014247122B2 (en) 2013-04-05 2018-12-06 Société des Produits Nestlé S.A. Compositions for use in stimulating bone growth
MX2016004444A (es) * 2013-10-08 2016-11-10 Ferring Bv Microparticulas que comprenden gnrh hechas mediante pgss.
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
CN112955181B (zh) 2019-03-26 2024-08-13 新型医药公司 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物
KR102628523B1 (ko) 2020-06-30 2024-01-24 주식회사 종근당 GnRH 유도체를 포함하는 주사용 조성물
WO2024063176A1 (ko) * 2022-09-21 2024-03-28 울산대학교 산학협력단 Pla 기반의 복합플라스틱의 제조방법, 그로부터 제조된 복합플라스틱 및 이를 포함하는 필름

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0720859B2 (ja) * 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
JPS63267720A (ja) 1987-04-24 1988-11-04 Morishita Seiyaku Kk エモルフアゾンの徐放性製剤
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
ATE168391T1 (de) 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
ATE161716T1 (de) 1992-08-07 1998-01-15 Takeda Chemical Industries Ltd Herstellung von mikrokapseln, die wasserlösliche arzneimittel enthalten
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
EP0711166A1 (en) 1993-07-22 1996-05-15 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
JPH10231242A (ja) * 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk 持続性ジクロフェナクナトリウム組成物
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
NZ505651A (en) 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
KR100321854B1 (ko) 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
HK1042237A1 (en) 1999-07-15 2002-08-09 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and use thereof
AU2001244572A1 (en) 2000-03-30 2001-10-15 Tanabe Seiyaku Co., Ltd. Microsphere preparations containing neurokinin 1 receptor antagonist
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
TW200526267A (en) 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
CN1620285A (zh) 2001-12-26 2005-05-25 武田药品工业株式会社 新微球和其生产方法
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
KR101041767B1 (ko) 2002-06-25 2011-06-17 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물의 제조 방법
JP4321622B2 (ja) 2007-04-27 2009-08-26 ソニー株式会社 照明装置および液晶表示装置

Also Published As

Publication number Publication date
US7662408B2 (en) 2010-02-16
JPWO2005074896A1 (ja) 2007-10-11
EP1714643A1 (en) 2006-10-25
EP1714643A4 (en) 2011-03-02
WO2005074896A1 (ja) 2005-08-18
US20060074027A1 (en) 2006-04-06
CN1938008A (zh) 2007-03-28
JP4966545B2 (ja) 2012-07-04
KR20060129015A (ko) 2006-12-14
CA2554262A1 (en) 2005-08-18
KR101162526B1 (ko) 2012-07-09
TW200529890A (en) 2005-09-16

Similar Documents

Publication Publication Date Title
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
BR0211317A (pt) Sistema para a liberação controlada de uma droga por meio de retenção gástrica
MXPA03007590A (es) Composiciones y metodos para mejorar suministro de droga a traves de y dentro de tejidos oculares.
BRPI0506305A (pt) artigos e métodos de tratamento da pele
PT1053746E (pt) Utilizacao de micro-esferas biodegradaveis libertando um agente anticanceroso para o tratamento do glioblastoma
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
WO2003034995A3 (en) Integrin targeting compounds
BR0309549B1 (pt) "artigo de fumar, e, método para controlar a velocidade de queima estática de um artigo de fumar".
AR019896A1 (es) Agente con efecto antidepresivo
BRPI0111116B8 (pt) imitadores de trombopoietina
CY1109955T1 (el) Δισκιο τροποποιημενης απελευθερωσης υδροχλωριουχου bupropion
BR0100877A (pt) Substâncias encapsuladas com liberaçãocontrolada
AR054233A1 (es) Composiciones de anticuerpos igg2
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BRPI0405450A (pt) Agente de revestimento
EA200300503A1 (ru) Новые лекарственные композиции на основе солей тиотропия и солей салметерола
DE60134324D1 (de) NEUE HEILMITTEL FüR KREBS
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
BR0010660A (pt) Processo para a fabricação de um artigo absorvente respirável
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
BR0215027A (pt) Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE, CONFORME ART. 10 DA RES. 124/06.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.